Karen Prange Net Worth

The estimated Net Worth of Karen Prange is at least $1.36 Milione dollars as of 19 July 2023. Ms. Prange owns over 129,466 units of Nevro Corp stock worth over $41,443 and over the last 12 years she sold NVRO stock worth over $1,019,405. In addition, she makes $302,071 as Independent Director at Nevro Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Prange NVRO stock SEC Form 4 insiders trading

Karen has made over 19 trades of the Nevro Corp stock since 2013, according to the Form 4 filled with the SEC. Most recently she sold 129,466 units of NVRO stock worth $9,063 on 19 July 2023.

The largest trade she's ever made was selling 129,466 units of Nevro Corp stock on 19 July 2023 worth over $9,063. On average, Karen trades about 8,187 units every 87 days since 2013. As of 19 July 2023 she still owns at least 8,799 units of Nevro Corp stock.

You can see the complete history of Ms. Prange stock trades at the bottom of the page.

Karen Prange biography

Karen N. Prange serves as Independent Director of the Company. From May 2016 to April 2018, Ms. Prange was Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein and a member of its Executive Committee. Prior to that, Ms. Prange was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business from June 2012 to May 2016. Prior to working at Boston Scientific, Ms. Prange also held several leadership positions in increasing levels of responsibility at Johnson and Johnson Company, most recently as General Manager of the Micrus Endovascular and Codman Neurovascular business. Ms. Prange currently serves on the boards of Atricure and Cantel Medical and is a strategic advisor for Nuvo Group. Ms. Prange earned her B.S. in Business Administration with honors from the University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College.

What is the salary of Karen Prange?

As the Independent Director of Nevro Corp, the total compensation of Karen Prange at Nevro Corp is $302,071. There are 12 executives at Nevro Corp getting paid more, with D.Keith Grossman having the highest compensation of $13,877,700.

How old is Karen Prange?

Karen Prange is 56, she's been the Independent Director of Nevro Corp since 2019. There are 17 older and 7 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.

What's Karen Prange's mailing address?

Karen's mailing address filed with the SEC is 7555, Innovation Way, Innovation Business Center, Mason, Warren County, Ohio, 45040, United States.

Insiders trading at Nevro Corp

Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo e & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.

What does Nevro Corp do?

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.

Complete history of Ms. Prange stock trades at Atricure Inc, Henry Schein, ViewRay, Boston Scientific, Cantel Medical Corp e Nevro Corp

Nevro Corp executives and stock owners

Nevro Corp executives and other stock owners filed with the SEC include:

• D.Keith Grossman,
  Chairman of the Board, President, Chief Executive Officer
• Niamh Pellegrini,
  Chief Commercial Officer
• Michael Carter,
  Vice President - Global Sales
• Christopher Christoforou,
  Vice President - Research and Development
• D. Keith Grossman,
  Chairman, CEO & Pres
• Patrick Schmitz,
  Vice President - Operations
• Kashif Rashid,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Andrew H. Galligan,
  Exec. Officer
• Kashif Rashid,
  Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Roderick H. MacLeod,
  Chief Financial Officer
• Elizabeth Weatherman,
  Independent Director
• Kevin O'Boyle,
  Independent Director
• Karen Prange,
  Independent Director
• Michael DeMane,
  Lead Independent Director
• Wilfred Jaeger,
  Independent Director
• Shawn McCormick,
  Independent Director
• Frank Fischer,
  Independent Director
• Brad Vale,
  Independent Director
• David Caraway,
  Chief Medical Officer
• Donald Middlebrook,
  Vice President - Clinical, Regulatory and Quality
• Juliet Cunningham,
  Vice President - Investor Relations
• Lori Ciano,
  Chief Human Resource Officer
• Roderick MacLeod,
  Chief Financial Officer
• Dr. David Caraway,
  Chief Medical Officer
• Lori M. Ciano,
  Chief HR Officer
• Patrick Schmitz,
  VP of Operations
• Jon R. Shear,
  VP of Corp. Devel.
• Michael Collier Carter,
  VP of Global Sales
• Julie D. Dewey,
  Chief Corp. Communications & Investor Relations Officer
• Sridhar Kosaraju,
  
• James Alecxih,
  Vice President, Sales
• Lisa D Earnhardt,
  Director
• Andre Walker,
  Senior VP,Research&Development
• Ali Behbahani,
  Director
• Kevin R Thornal,
  President & CEO
• Rami Elghandour,
  President
• Michael Enxing,
  VP of Sales & Marketing
• Arch Management Iv, L.L.C.T...,
  
• City Capital Llc Bay City C...,
  
• Holdings A/S Novo,
  10% owner
• Partners Ii Lp Amv,
  
• City Capital Llc Bay City C...,
  
• Nathan B Pliam,
  Director
• & Johnson Johnson & Johnson...,
  
• Balakrishnan Shankar,
  VP, Operations
• Andrew H Galligan,
  Chief Financial Officer
• Doug Alleavitch,
  VP, Quality
• Kirt P Karros,
  
• Christofer Christoforou,
  SVP, Chief Operating Officer
• Greg Siller,
  SVP & Chief Commercial Officer
• Richard B. Carter,
  Chief Accounting Officer
• Susan E Siegel,